Castle Creek Pharmaceuticals Announces First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for Epidermolysis Bullosa Simplex; International randomized, double-blind, parallel group Phase 2/3 clinical trial to evaluate safety and efficacy of

Press/Media: Press / Media

PeriodJun 5 2017

Media coverage

2

Media coverage

  • TitleCastle Creek Pharmaceuticals Announces First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for Epidermolysis Bullosa Simplex; International randomized, double-blind, parallel group Phase 2/3 clinical trial to evaluate safety and efficacy of
    Media name/outletPR Newswire
    CountryUnited States
    Date6/5/17
    PersonsJohn C Browning
  • TitleCastle Creek Pharmaceuticals Announces First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for Epidermolysis Bullosa Simplex; International randomized, double-blind, parallel group Phase 2/3 clinical trial to evaluate safety and efficacy of
    Media name/outletPR Newswire
    CountryUnited States
    Date6/5/17
    PersonsJohn C Browning